TY - JOUR T1 - Intensive glucose control in patients with type 2 diabetes is associated with a reduction in albuminuria and may be associated with reduced end-stage renal disease JF - Evidence Based Medicine JO - Evid Based Med SP - 105 LP - 106 DO - 10.1136/eb-2012-100904 VL - 18 IS - 3 AU - Clement Lo AU - Sophia Zoungas Y1 - 2013/06/01 UR - http://ebm.bmj.com/content/18/3/105.abstract N2 - Commentary on: Coca SG, Ismail-Beigi F, Haq N, et al. Role of intensive glucose control in development of renal end points in type 2 diabetes mellitus: systematic review and meta-analysis intensive glucose control in type 2 diabetes. Ann Intern Med 2012; 172:761–9.OpenUrlCrossRefWeb of Science Diabetic nephropathy is the commonest cause of end-stage renal disease (ESRD)1 making the prevention of its onset and progression, critically important. While epidemiological studies have linked hyperglycaemia to diabetic nephropathy, randomised controlled trials (RCTs) to date have reported the beneficial effects of intensive glycaemic control on early stages of nephropathy, that is, albuminuria levels but not ESRD. On the basis of this evidence, guidelines have recommended a glycated haemoglobin (HbA1c) of <7% to prevent renal outcomes. This systematic review specifically examines whether intensive glycaemic control improves a range of early and advanced renal outcomes in patients with type 2 diabetes (T2DM). RCTs meeting the pre-specified inclusion criteria (randomisation of patients with T2DM to intensive or … ER -